Seminars in Interventional Radiology最新文献_第7页

Hepatocellular Carcinoma: Advances in Systemic Therapy. 肝细胞癌：系统疗法的进展。

IF 1 4区医学

Seminars in Interventional Radiology Pub Date : 2024-03-14 eCollection Date: 2024-02-01 DOI: 10.1055/s-0044-1779713

Insija Ilyas Selene, Merve Ozen, Reema A Patel

{"title":"Hepatocellular Carcinoma: Advances in Systemic Therapy.","authors":"Insija Ilyas Selene, Merve Ozen, Reema A Patel","doi":"10.1055/s-0044-1779713","DOIUrl":"10.1055/s-0044-1779713","url":null,"abstract":"Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing over 90% of cases globally and ranking as the third leading cause of cancer-related death. This article reviews the evolving landscape of systemic therapies for advanced HCC, emphasizing recent advancements and their impact on patient outcomes. The advent of molecular targeted therapies has transformed HCC management, with sorafenib being the first FDA-approved molecular targeted therapy, setting a standard for a decade. However, recent breakthroughs involve the combination of atezolizumab and bevacizumab, demonstrating superior outcomes over sorafenib, leading to FDA approval in 2020. Another notable combination is tremelimumab and durvalumab, showing efficacy in a multinational phase III trial. Beyond these combinations, this article explores the role of other first-line treatments and subsequent therapies after progression. The evolving landscape of systemic therapies for HCC reflects a paradigm shift, with immunotherapy combinations emerging as key players alongside targeted therapies. This article highlights the complexity of treatment decisions, considering individual patient characteristics and disease etiology, and underscores the ongoing quest to optimize both systemic and local-regional therapies for improved long-term outcomes in HCC patients.","PeriodicalId":48689,"journal":{"name":"Seminars in Interventional Radiology","volume":"41 1","pages":"56-62"},"PeriodicalIF":1.0,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10940040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatocellular Carcinoma from a Hepatologist's Perspective 从肝病专家的角度看肝细胞癌

IF 1.4 4区医学

Seminars in Interventional Radiology Pub Date : 2024-01-24 DOI: 10.1055/s-0043-1777846

Giovanni A. Roldan, Jacquelin Blomker, Elizabeth S. Aby

{"title":"Hepatocellular Carcinoma from a Hepatologist's Perspective","authors":"Giovanni A. Roldan, Jacquelin Blomker, Elizabeth S. Aby","doi":"10.1055/s-0043-1777846","DOIUrl":"https://doi.org/10.1055/s-0043-1777846","url":null,"abstract":"Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, represents a growing health challenge worldwide. The incidence of HCC is rising, which, in turn, has led to a corresponding increase in the associated number of deaths. HCC will become the third leading cause of cancer-related deaths in the United States by 2030. HCC usually develops in the setting of chronic liver disease. Individuals at increased risk of HCC are recommended to undergo surveillance with ultrasound every 6 months along with serum α-fetoprotein testing. Computed tomography (CT) and magnetic resonance imaging (MRI) are considered alternatives based on specific patient factors. Lesions suspicious for HCC are recommended to undergo a diagnostic testing, which includes contrast-enhanced multiphase CT or MRI and liver biopsy when findings are indeterminate. The Barcelona Clinic Liver Cancer prognosis and treatment strategy is the most used assessment for patients with HCC (<xref idref=\"FI001521-2\">Fig. 2</xref>). Curative therapies include resection, liver transplantation, and ablation. Locoregional therapies, such as transarterial chemoembolization and radioembolization, can be used for patients with intermediate-stage HCC. For patients with advanced-stage HCC, systemic therapy is often used. This review aims to provide an overview of HCC from a hepatologist's perspective, including epidemiology, screening, surveillance, diagnosis, and management. ","PeriodicalId":48689,"journal":{"name":"Seminars in Interventional Radiology","volume":"387 1 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139559965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chemoembolization Plus Ablation: Current Status 化疗栓塞加消融：现状

IF 1.4 4区医学

Seminars in Interventional Radiology Pub Date : 2024-01-24 DOI: 10.1055/s-0043-1777715

Farnaz Dadrass, Pascal Acree, Edward Kim

{"title":"Chemoembolization Plus Ablation: Current Status","authors":"Farnaz Dadrass, Pascal Acree, Edward Kim","doi":"10.1055/s-0043-1777715","DOIUrl":"https://doi.org/10.1055/s-0043-1777715","url":null,"abstract":"Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. The treatment landscape for HCC has evolved significantly over the past decade, with several modalities available to treat various stages of disease. The Barcelona Clinic Liver Cancer (BCLC) system provides a foundation for treatment guidance. However, given the complex nature of HCC, a more nuanced approach is often required, especially for lesions sized between 3 and 5 cm. This review aims to analyze the available treatments for early-stage HCC lesions between 3 and 5 cm, with a focus on the therapeutic potential and efficacy of transarterial chemoembolization (TACE)–ablation. Additional therapies including TACE, ablation, transarterial radioembolization, and surgical resection are also reviewed and compared with TACE–ablation. TACE–ablation is a viable therapeutic option for early-stage HCC lesions between 3 and 5 cm. Surgical resection remains the gold standard. Although recent studies suggest radiation segmentectomy may be a curative approach for this patient population, further studies are needed to compare the relative efficacies between TACE–ablation and radiation segmentectomy. ","PeriodicalId":48689,"journal":{"name":"Seminars in Interventional Radiology","volume":"14 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139559942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ablation versus Radiation Segmentectomy for Small Liver Tumors 小肝脏肿瘤的消融与放射分段切除术

IF 1.4 4区医学

Seminars in Interventional Radiology Pub Date : 2024-01-24 DOI: 10.1055/s-0043-1777714

引用次数: 0

Non-Thermal Liver Ablation: Existing and New Technology 非热肝脏消融术：现有技术和新技术

IF 1.4 4区医学

Seminars in Interventional Radiology Pub Date : 2024-01-24 DOI: 10.1055/s-0043-1777844

Tiffany Nakla, Jacqueline J. Chow, Kathleen Pham, Nadine Abi-Jaoudeh

{"title":"Non-Thermal Liver Ablation: Existing and New Technology","authors":"Tiffany Nakla, Jacqueline J. Chow, Kathleen Pham, Nadine Abi-Jaoudeh","doi":"10.1055/s-0043-1777844","DOIUrl":"https://doi.org/10.1055/s-0043-1777844","url":null,"abstract":"Cancer has and continues to be a complex health crisis plaguing millions around the world. Alcohol ablation was one of the initial methods used for the treatment of liver lesions. It was surpassed by thermal ablation which has played a big role in the therapeutic arsenal for primary and metastatic liver tumors. However, thermal ablation has several shortcomings and limitations that prompted the development of alternative technologies including electroporation and histotripsy. Percutaneous alcohol injection in the liver lesion leads to dehydration and coagulative necrosis. This technology is limited to the lesion with relative sparing of the surrounding tissue, making it safe to use adjacent to sensitive structures. Electroporation utilizes short high-voltage pulses to permeabilize the cell membrane and can result in cell death dependent on the threshold reached. It can effectively target the tumor margins and has lower damage rates to surrounding structures due to the short pulse duration. Histotripsy is a novel technology, and although the first human trial was just completed, its results are encouraging, given the sharp demarcation of the targeted tissue, lack of thermal damage, and potential for immunomodulation of the tumor microenvironment. Herein, we discuss these techniques, their uses, and overall clinical benefit. ","PeriodicalId":48689,"journal":{"name":"Seminars in Interventional Radiology","volume":"9 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139559968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions 肝脏导向疗法与全身疗法相结合：现状与未来方向

IF 1.4 4区医学

Seminars in Interventional Radiology Pub Date : 2024-01-24 DOI: 10.1055/s-0043-1777711

Shamar Young, Jack Hannallah, Dan Goldberg, Mohammad Khreiss, Rachna Shroff, Junaid Arshad, Aaron Scott, Gregory Woodhead

{"title":"Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions","authors":"Shamar Young, Jack Hannallah, Dan Goldberg, Mohammad Khreiss, Rachna Shroff, Junaid Arshad, Aaron Scott, Gregory Woodhead","doi":"10.1055/s-0043-1777711","DOIUrl":"https://doi.org/10.1055/s-0043-1777711","url":null,"abstract":"In the past several decades, major advances in both systemic and locoregional therapies have been made for many cancer patients. This has led to modern cancer treatment algorithms frequently calling for active interventions by multiple subspecialists at the same time. One of the areas where this can be clearly seen is the concomitant use of locoregional and systemic therapies in patients with primary or secondary cancers of the liver. These combined algorithms have gained favor over the last decade and are largely focused on the allure of the combined ability to control systemic disease while at the same time addressing refractory/resistant clonal populations. While the general concept has gained favor and is likely to only increase in popularity with the continued establishment of viable immunotherapy treatments, for many patients questions remain. Lingering concerns over the increase in toxicity when combining treatment methods, patient selection, and sequencing remain for multiple cancer patient populations. While further work remains, some of these questions have been addressed in the literature. This article reviews the available data on three commonly treated primary and secondary cancers of the liver, namely, hepatocellular carcinoma, cholangiocarcinoma, and metastatic colorectal cancer. Furthermore, strengths and weaknesses are reviewed and future directions are discussed. ","PeriodicalId":48689,"journal":{"name":"Seminars in Interventional Radiology","volume":"58 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139559964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endometriosis: An Overview. 子宫内膜异位症：概述。

IF 1 4区医学

Seminars in Interventional Radiology Pub Date : 2024-01-24 eCollection Date: 2023-12-01 DOI: 10.1055/s-0043-1777748

Tanvir Agnihotri, Abheek Ghosh, Ashley Lamba, Charles E Ray

引用次数: 0

A Review of Resection and Surgical Ablation for Primary and Secondary Liver Cancers 原发性和继发性肝癌的切除和手术消融回顾

IF 1.4 4区医学

Seminars in Interventional Radiology Pub Date : 2024-01-24 DOI: 10.1055/s-0043-1777747

McKenzie J. White, Eric H. Jensen, David G. Brauer

引用次数: 0

Thermal Ablation in the Liver: Heat versus Cold—What Is the Role of Cryoablation? 肝脏热消融：热与冷--低温消融的作用是什么？

IF 1.4 4区医学

Seminars in Interventional Radiology Pub Date : 2024-01-24 DOI: 10.1055/s-0043-1777845

Donna L. D'Souza, Ranjan Ragulojan, Chunxiao Guo, Connie M. Dale, Christopher J. Jones, Reza Talaie

引用次数: 0

Intravascular Ultrasound-Guided Retrieval of a Radiolucent Foreign Body from the Superior Vena Cava. 血管内超声引导下从上腔静脉取出放射性异物。

IF 1 4区医学

Seminars in Interventional Radiology Pub Date : 2024-01-24 eCollection Date: 2023-12-01 DOI: 10.1055/s-0043-1777713

Sara Rostami, Jacob Miller, Nikhil Grandhi, Charles E Ray, Ali Kord

引用次数: 0